IE
VBIV

Israel Englander’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Israel Englander’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,642
Closed -$10K – 6698
2024
Q1 		$10K Sell
16,642
-5,396
-24% -$3.31K ﹤0.01% 5926
2023
Q4 		$12.9K Sell
22,038
-49,384
-69% -$29.7K ﹤0.01% 5699
2023
Q3 		$47.6K Sell
71,422
-17,783
-20% -$21.8K ﹤0.01% 5486
2023
Q2 		$293K Buy
89,205
+88,664
+16,389% +$268K ﹤0.01% 4901
2023
Q1 		$5K Sell
541
-12,443
-96% -$176K ﹤0.01% 6139
2022
Q4 		$152K Sell
12,984
-24,341
-65% -$429K ﹤0.01% 5432
2022
Q3 		$790K Sell
37,325
-22,033
-37% -$594K ﹤0.01% 4542
2022
Q2 		$1.44M Buy
59,358
+40,313
+212% +$1.37M ﹤0.01% 4031
2022
Q1 		$948K Sell
19,045
-39,005
-67% -$1.93M ﹤0.01% 4587
2021
Q4 		$4.08M Buy
58,050
+17,866
+44% +$1.51M ﹤0.01% 3116
2021
Q3 		$3.75M Buy
40,184
+15,830
+65% +$1.5M ﹤0.01% 3210
2021
Q2 		$2.45M Buy
24,354
+13,135
+117% +$1.28M ﹤0.01% 3711
2021
Q1 		$1.05M Buy
+11,219
New +$1.14M ﹤0.01% 4176
2020
Q4 		– Sell
-62,776
Closed -$5.39K – 5682
2020
Q3 		$5.39K Buy
62,776
+46,358
+282% +$5.4M 0.01% 1773
2020
Q2 		$1.53M Buy
+16,418
New +$904K ﹤0.01% 2724
2019
Q2 		– Sell
-26,123
Closed -$1.47M – 4565
2019
Q1 		$1.47M Buy
26,123
+889
+4% +$48.1K ﹤0.01% 2627
2018
Q4 		$1.21M Buy
25,234
+19,998
+382% +$1.1M ﹤0.01% 2490
2018
Q3 		$380K Sell
5,236
-12,468
-70% -$822K ﹤0.01% 3376
2018
Q2 		$1.46M Buy
17,704
+9,607
+119% +$928K ﹤0.01% 2614
2018
Q1 		$850K Sell
8,097
-90
-1% -$10.7K ﹤0.01% 2779
2017
Q4 		$1.05M Buy
8,187
+3,940
+93% +$484K ﹤0.01% 2677
2017
Q3 		$490K Buy
+4,247
New +$510K ﹤0.01% 2850
2017
Q2 		– Sell
-5,182
Closed -$853K – 3962
2017
Q1 		$853K Buy
5,182
+3,774
+268% +$511K ﹤0.01% 2498
2016
Q4 		$131K Buy
+1,408
New +$134K ﹤0.01% 3162

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's VBIV Position: Q2 2024 in Review

Israel Englander sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2024, closing a stake of 16,642 shares — an estimated $10K sold.

Israel Englander first reported a position in VBIV in Q4 2016 and held it in 24 quarters. The position peaked at $4.08M in Q4 2021. 41 funds tracked by Wall St. Rank hold VBIV as of Q2 2024.

  • Israel Englander reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 16,642 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2024, an estimated $10K.
  • Israel Englander first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2016 and held it in 24 quarters.
  • Israel Englander's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $4.08M in Q4 2021.
  • 41 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.